NASDAQ : EXAS
Exact Sciences Corporation — Key statistics
Healthcare · Diagnostics & Research · United States
Last price 104.91 USD (At close: Mar 20, 2026) · Market cap 20.03B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | n/a |
| Enterprise Value | n/a |
Dates
| Measure | Value |
|---|
| Earnings Date | Apr 30, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 190.89M |
| Shares Change (YoY) | +2.44% |
| Shares Change (QoQ) | +0.25% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.43 |
| Quick Ratio | 1.97 |
| Debt / Equity | 1.06 |
| Debt / EBITDA | 22.34 |
| Debt / FCF | 7.10 |
| Interest Coverage | -3.81 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -8.66% |
| Return on Assets (ROA) | -1.59% |
| Return on Invested Capital (ROIC) | -1.86% |
| Return on Capital Employed (ROCE) | -2.88% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $450,971 |
| Profits Per Employee | -$28,882 |
| Employee Count | 7,200 |
| Asset Turnover | 0.55 |
| Inventory Turnover | 5.99 |
Taxes
| Measure | Value |
|---|
| Income Tax | 4.06M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.44 |
| 52-Week Price Change | +129.56% |
| 50-Day Moving Average | 103.02 |
| 200-Day Moving Average | 74.29 |
| Relative Strength Index (RSI) | 76.40 |
| Average Volume (20 Days) | 3,095,929 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 7.40M |
| Short Previous Month | 7.12M |
| Short % of Shares Out | 3.88% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.23 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 3.25B |
| Gross Profit | 2.26B |
| Operating Income | -150.12M |
| Pretax Income | -203.89M |
| Net Income | -207.95M |
| EBITDA | 71.46M |
| EBIT | -150.12M |
| Loss Per Share | -$1.10 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 964.71M |
| Total Debt | 2.53B |
| Net Cash | -1.57B |
| Net Cash Per Share | -$8.23 |
| Equity (Book Value) | 2.40B |
| Book Value Per Share | 12.58 |
| Working Capital | 914.70M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 491.44M |
| Capital Expenditures | -134.66M |
| Depreciation & Amortization | 221.58M |
| Net Borrowing | -249.17M |
| Free Cash Flow | 356.78M |
| FCF Per Share | $1.87 |
Margins
| Measure | Value |
|---|
| Gross Margin | 69.69% |
| Operating Margin | -4.62% |
| Pretax Margin | -6.28% |
| Profit Margin | -6.40% |
| EBITDA Margin | 2.20% |
| EBIT Margin | -4.62% |
| FCF Margin | 10.99% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.44% |
| Shareholder Yield | -2.44% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $86.62 |
| Price Target Difference | -17.43% |
| Analyst Consensus | Hold |
| Analyst Count | 17 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 1.43 |
| Piotroski F-Score | 5 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |